Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teplizumab in recently diagnosed Stage 3 Type 1 Diabetes
NCT07088068Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Aug 2025
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 3 trial of teplizumab in type 1 diabetes mellitus (T1D), sponsored by Sanofi. Started Aug 2025; status: recruiting.
02
Drugs
teplizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07088068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07088068.